SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Entry into a Material Definitive Agreement

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On April 27, 2017, Selecta Biosciences, Inc. (the “Company”) entered into a Patent License Agreement (the “License Agreement”) with the U.S. Department of Health and Human Services, as represented by the National Cancer Institute, an Institute or Center of the National Institutes of Health (the “NIH”). Under the terms of the License Agreement, the NIH granted to the Company an exclusive worldwide license under specified patent rights and a non-exclusive worldwide license under specified other patent rights in the field of use of anti-mesothelin targeted immunotoxins for the treatment of mesothelin-expressing cancers. The Company has the right to grant sublicenses under the licenses granted by the NIH with NIH’s prior consent, not to be unreasonably withheld. The license grant is subject to typical statutory requirements and reserved rights as required under federal law and NIH requirements. In addition, if the NIH determines that the public health and safety so require, the NIH may require the Company to grant sublicenses to responsible applicants, on reasonable terms, in any licensed field under the licensed patent rights, unless the Company can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the licensed patent rights.
In consideration for the rights granted under the License Agreement, the Company agreed to pay an upfront payment of $50,000, earned royalties equal to a percentage, in the low single digits, of net sales (subject to certain annual minimum royalty payments), payments of up to an aggregate of $9,250,000 upon achievement of specified benchmarks, and a percentage, ranging from the mid single digits to mid teens, of revenues from sublicensing arrangements. The Company is obligated to use commercially reasonable efforts to exploit, and make publicly available, the inventions described in the licensed patent rights. The Company may not transfer or assign the License Agreement to a third party without the NIH’s consent, and if the NIH consents to any assignment, the Company is obligated to pay the NIH a percentage in the low single digits of the consideration received by the Company for such assignment.
The term of the License Agreement will extend to the date of expiry of the last-to-expire patent in the licensed patent rights, unless either party terminates the License Agreement earlier. The NIH may terminate the License Agreement if the Company is in default of the performance of any material obligations under the License Agreement, including certain specified benchmark and other obligations, if the default has not been remedied within ninety days after the date of notice in writing of the default. In addition, the NIH may terminate the License Agreement or modify, at its option, the License Agreement, if the NIH determines that such termination or modification is necessary to meet the requirements for public use specified by federal regulations issued after the date of the License Agreement and these requirements are not reasonably satisfied by the Company. The Company may terminate the License Agreement or any licenses in any country or territory by giving the NIH sixty days written notice.

About SELECTA BIOSCIENCES, INC. (NASDAQ:SELB)

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Recent Trading Information

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) closed its last trading session up +0.14 at 12.20 with 169,253 shares trading hands.

An ad to help with our costs